DE LUCA, GIACOMO
 Distribuzione geografica
Continente #
EU - Europa 700
NA - Nord America 574
AS - Asia 122
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
Totale 1.403
Nazione #
US - Stati Uniti d'America 571
SE - Svezia 447
IT - Italia 133
CN - Cina 63
FI - Finlandia 40
DE - Germania 24
PH - Filippine 17
NL - Olanda 10
SG - Singapore 10
IE - Irlanda 9
FR - Francia 8
IN - India 8
KR - Corea 8
UA - Ucraina 7
GB - Regno Unito 6
NO - Norvegia 6
IR - Iran 5
MK - Macedonia 4
TR - Turchia 4
CA - Canada 2
EU - Europa 2
HK - Hong Kong 2
HU - Ungheria 2
JP - Giappone 2
PE - Perù 2
TN - Tunisia 2
AL - Albania 1
DZ - Algeria 1
GR - Grecia 1
ID - Indonesia 1
IL - Israele 1
MX - Messico 1
RU - Federazione Russa 1
SI - Slovenia 1
UZ - Uzbekistan 1
Totale 1.403
Città #
Lawrence 99
Princeton 99
New York 74
Shanghai 62
Ashburn 57
Helsinki 40
Milan 31
Rome 14
Dublin 9
Los Angeles 9
Makati City 9
Seattle 8
Seongnam-si 8
Oslo 6
Pune 6
Howell 5
Verona 5
Ancona 4
Dronten 4
Istanbul 4
Mestrino 4
Quezon City 4
Vaprio d'Adda 4
Angera 3
Gallarate 3
Osimo 3
Skopje 3
Springfield 3
Vittoria 3
Angers 2
Arezzo 2
Arnsberg 2
Cabanatuan City 2
Castel Mella 2
Catania 2
Dalmine 2
Enschede 2
Florence 2
Honcho 2
Lima 2
Marana 2
Mykolayiv 2
Orani 2
Padova 2
Paris 2
Pécs 2
San Mateo 2
Segrate 2
Singapore 2
Torre Del Greco 2
Washington 2
West Jordan 2
York 2
Aci Catena 1
Amsterdam 1
Athens 1
Balasore 1
Borås 1
Capaccio 1
Certaldo 1
Dallas 1
Falkenstein 1
Fiumefreddo Di Sicilia 1
Frankfurt am Main 1
Galliate 1
Giv‘atayim 1
Hanover 1
Issogne 1
Jakarta 1
Kish 1
Lainate 1
Laurel 1
Ljubljana 1
London 1
Maidenhead 1
Monterrey 1
Mountain View 1
Naaldwijk 1
Pacific Palisades 1
Paliano 1
Quanzhou 1
Redwood City 1
Sacramento 1
San Giovanni In Persiceto 1
San Jose 1
San Sperate 1
Secaucus 1
Seriate 1
Sezze 1
Tashkent 1
Tenhult 1
Tirana 1
Toronto 1
Torre Boldone 1
Trumbull 1
Yonkers 1
Totale 674
Nome #
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 41
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 37
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 32
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 30
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli 28
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 26
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 25
Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation 24
Arrhythmias in Myocarditis: State of the Art 23
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study 22
The spectrum of covid-19-associated myocarditis: A patient-tailored multidisciplinary approach 22
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 21
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease 20
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 20
Does the impact of COVID-19 on patients with systemic sclerosis change over time? 19
Exercise Stress Test Late after Arrhythmic versus Nonarrhythmic Presentation of Myocarditis 19
Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al 19
Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases 19
The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis 19
Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis 18
C3-glomerulopathy and MGUS: The skin beyond the kidney 18
Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series 18
Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis 18
A Novel Histiocytosis With Synovial and Skin Involvement 18
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 17
Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias 17
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 17
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 17
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 16
Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study 16
B cells in systemic sclerosis: A possible target for therapy 16
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 16
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 16
Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement. 16
Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it? 15
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance: Report of Two Cases and Rationale for Its Therapeutic Use 15
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 15
Inflammation as a Predictor of Recurrent Ventricular Tachycardia After Ablation in Patients With Myocarditis 15
Anti-Ku syndrome with elevated CK: Association with myocardial involvement in systemic sclerosis 15
Drug retention rates of biological agents in adult onset Still's disease 15
Heart Involvement in Systemic Sclerosis: the Role of Magnetic Resonance Imaging 15
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 15
Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies 15
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 14
Advances in potential targeted therapies for Erdheim-Chester disease 14
Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy 14
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 14
Cardiac immune-related adverse events: an immune-cardio-oncology puzzle 14
Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience 14
Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases 14
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 13
Unexpected acute lymphocytic virus-negative myocarditis in a patient with limited cutaneous systemic sclerosis: a case report 13
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 13
Hybrid FDG-PET/MR or FDG-PET/CT to Detect Disease Activity in Patients With Persisting Arrhythmias After Myocarditis 13
Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers 13
Prognostic Role of Ventricular Ectopic Beats in Systemic Sclerosis: A Prospective Cohort Study Shows ECG Indexes Predicting the Worse Outcome 13
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition 13
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies 13
Generalized morphea after COVID-19 vaccines: a case series 12
Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series 12
QTc interval prolongation in Systemic Sclerosis: Correlations with clinical variables and arrhythmic risk 12
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 12
Therapeutic strategies for virus-negative myocarditis: a comprehensive review 12
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study 12
Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst 12
Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature 11
The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease 11
Low prevalence of arrhythmias in clinically stable COVID-19 patients 11
Telemedicine in myocarditis: Evolution of a mutidisciplinary “disease unit” at the time of COVID-19 pandemic 11
Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study 11
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic 11
ENVIRONMENTAL POLLUTION AND SYSTEMIC SCLEROSIS: A PILOT STUDY ON BENZENE AND PARTICULATE EXPOSURE AS RISK FACTORS FOR THE SYSTEMIC MANIFESTATIONS 11
Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis 11
Severe acute respiratory syndrome coronavirus-2-induced flare of systemic sclerosis 11
Improvements of vascular outcomes in systemic sclerosis: halfway through, but still far to go 11
Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis 11
Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities 10
Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group 10
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 10
Successful use of sirolimus in a patient with cardiac microangiopathy in primary antiphospholipid syndrome 10
Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition 10
Myocarditis: An Interleukin-1-Mediated Disease? 10
Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease (Arthritis Research and Therapy (2019) 21 (54) DOI: 10.1186/s13075-019-1843-9) 10
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 10
Diagnostic approach and novel therapeutic option for cardiac inflammatory disorders. Comment on “Antisynthetase syndrome and cardiac involvement: a rare association” by Meudec et al. Joint Bone Spine 2018. doi: 10.1016/j.jbspin.2018.09.019 10
Patient-reported outcome instruments in clinical trials of systemic sclerosis 10
Cardiac troponin T and NT-proBNP as diagnostic and prognostic biomarkers of primary cardiac involvement and disease severity in systemic sclerosis: A prospective study 10
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19 10
Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression 10
Troponin in Stable Ischemic Heart Disease and Diabetes 10
Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance 10
Cardiac Safety of mRNA-based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis 10
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 9
Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in systemic sclerosis: Frequency, clinical and prognostic correlates 9
Pruritus characteristics in a large Italian cohort of psoriatic patients 9
Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis 9
Relationship Between Ventricular Arrhythmias, Conduction Disorders, and Myocardial Fibrosis in Patients With Systemic Sclerosis: The Role of Cardiac Magnetic Resonance 9
Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim-Chester Disease 9
Large Vessel Vasculitis Affecting the Aorta and Its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature 9
ASSOCIAZIONE TRA MALATTIA IGG4-CORRELATA E IMMUNOTERAPIA ALLERGENE-SPECIFICA. STUDIO EPIDEMIOLOGICO DI UN CENTRO DI RIFERIMENTO ITALIANO. 9
Totale 1.494
Categoria #
all - tutte 20.036
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.036


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202020 3 0 0 0 0 0 0 0 1 0 15 1
2020/202148 3 0 5 10 0 12 8 3 1 0 4 2
2021/2022249 1 0 102 46 9 16 4 7 11 31 5 17
2022/2023784 250 176 55 4 16 97 40 72 35 11 15 13
2023/2024560 25 56 75 67 65 111 42 82 5 32 0 0
Totale 1.680